Oil of fish during pregnancy may not stimulate the vision of babies

NEW YORK - moms who take fish oil supplements may be not much done to sharpen the vision of their baby, a new study suggests.

The fly of some previous research findings that suggested Docosahexaenoic acid (DHA), found in fish oil, improves vision in premature infants who receive supplements in their first months of life.

DHA is an omega-3 fatty acid involved in the brain and Visual development. Given that the substance crosses the placenta, primarily more later during the pregnancy, preterm Miss on a large part of their prenatal supply.

Therefore extra DHA after birth could help make up for this.

In the new study, Australian researchers looked at whether prenatal fish oil helps improve vision in infants born at term.

They have tested Visual acuity in 185 4 - month - olds whose mothers had been assigned at random to take rich in DHA fish oil capsules or placebo (capsules of vegetable oil) daily progestogen until delivery.

Overall, there was no benefit of DHA on the vision of newborns, the researchers report in the American Journal of Clinical Nutrition.

It is not clear why supplements have an impact, despite the benefits seen in premature infants given DHA after birth.

But one reason may be that preterm need the extra DHA, while babies born at term get all that they need for normal Visual development while still in the womb, according to Dr. Maria Makridesthe principal investigator of the study.

"I think that if women are better nourished and have a good scheme varied, then DHA supplementation during pregnancy to improve visual development for their unborn baby is not necessary," Makrides, women and children Health Research Institute of North AdelaideEn Australiatold Reuters Health in an e-mail.

Researchers are still studying if there could be other benefits to the development of infants. But studies have so far are mixed.

In a study published last year, the Makrides team found no evidence this oil of fish during pregnancy babies relaunched cognitive and language skills at the age of 18 months (see history of Reuters Health, October 19, 2010).

Makrides said that this and other studies are highlighting the fact that in term infants born to mothers well fed generally do well development delay - and it can be difficult to improve with DHA supplements.

There may be other benefits of fish during pregnancy oil. Some studies have suggested that it may reduce the risk of preterm birth, for example, but it is still on this issue.

In General, experts recommend that pregnant women strive to 200 milligrams of DHA per day. Certain prenatal vitamins now wear the fatty acid, which is also present in fish, especially the more fatty such as salmon, mackerel and tuna.

However, since the fish may be contaminated with mercury, doctors advise pregnant women to limit to two meals of fish per week. They should also choose fish have Omega-3, but which are likely to have low mercury levels, such as salmon, canned light tuna and shrimp.

Some fish - shark, swordfish, mackerel King and Tile - should be completely avoided during pregnancy because they may have high concentrations of mercury.

Makrides, stated that his team continues to follow children in this study to see if the oil of fish during pregnancy makes no cognitive difference and four language skills at the age.

As for the Visual development, fish oil has any benefit for infants born at term, it would be more evident in early life.

"At the end of childhood," Makrides said, "it would be much more difficult to find differences between groups, such as Visual development would be well advanced."

Legislators run scared of reforming Medicare

WASHINGTON- a democratic victory in a reliable Republican district House of representatives this week has legislators cops to reform Medicare, greatly reducing the chances of a global agreement to reduce the deficit in the long term.

Rarely in recent years was a special election unique, off the coast of the year - such as in a district of the House Tuesday in the State of New York - raised these earthquakes of policies at the national level or have had these efforts to bring us federal debt under the control of the negative impact.

Democrat Kathy Hochul won a solidly Republican district after hammering his opponent to save a Republican plan in the House, to scale back Medicare costs. Medicare is a federal program which is the biggest single driver of deficit, but most voters want left intact.

Without a sincere effort to curb the growth of Medicare, which provides health insurance, to elderly and disabled US $ 47 million it will run short of money in 13 years.

Remained unchanged, Medicare, social security retirement program and the program of insurance of federal State of Medicaid for the poor would consume 100 percent of all tax revenues by 2047, according to the non-partisan Government Accountability Office.

Republicans recaptured control of the House in 2010 in part by Democrats accusing bar to slash Medicare and interfere with the doctor-patient relationship under health reform law signed year last by President Barack Obama. The Act is often derided by opponents as "obamacare."

Democrats believe that the political situation has been changed.

At issue is a Republican proposal put forward in April by House Budget Committee Chairman Paul Ryan would fundamentally reshape Medicare into an agreement in which seniors receive government benefits to help pay for private health insurance.

The impartiality that Congressional Budget Office estimated that the Ryan budget would eventually double Medicare small expenditure for the elderly.

Polls show that while voters want action to bring down the deficit - defined for $ 1.4 billion this year, overwhelmingly that they oppose any changes to Medicare.

Tim Pawlenty and Mitt Romney, regarded as the major candidates for the Republican presidential nomination in 2012, have backed away from Ryan plan.

Although the Senate Republicans appear to be maintained by Ryan plan in a vote Wednesday, some have conceded that their vote was the unity of the party more than real support to overhaul Medicare. The Senate under democratic control defeated the proposal by Ryan passed to the House by a vote of 57 to 40, with five Republican senators voting against it.

"ARTICLE OF FAITH".

Republican Senator Bob Corker said there was no Republicans of the Senate who considers an "article of faith".

A Republican strategist, speaking on condition of anonymity, said that Republicans would rather campaign the year next to the high unemployment rate that "tell voters why they want to dismantle Medicare.".

"The Republican budget is a political responsibility and toxic for the GOP," Democratic Senator Patty Murray said, referring to the nickname of Grand Old Party of Republicans. Competition of the House on Tuesday "remembered as a turning point in the next election."

With the Democrats having now every policy encourages not to address the costs of Medicare and wishing to avoid the problem of many Republicans, said analysts election on Tuesday was also a decisive moment - and non-positive - for the long-term deficit.

"It is amazing what can have a ripple effect, a special election", David Gergen, a political analyst and Adviser to four Presidents of the United States, told Reuters.

"The election of New York the makes more difficult to reach a global agreement on the reduction of the deficit - before the elections in 2012 and what happens after 2012 is therefore uncertain." This makes it more likely that they could kick the can on the road, in 2013 or 2014. ?

With the largest insurance and one of the fastest growing budget components, the important deficit reduction simply cannot be achieved without some savings in the programme.

Recent elections have shown what a politically explosive issue Medicare is - and the part that attempts to change the fact at his peril.

In 2010, Democrats accused Republicans of wanting to "death panels" for the elderly in their health care proposals. The benefits of the bitter struggle on the right lead healthcare helped helped new big Republican wins the legislative elections last November.

This week, a non-profit group Liberal, in an attack on the Ryan plan, has published an advertisement showing an old woman thrown a cliff of her wheelchair - an image that could be taken up by the Democrats, as the 2012 elections draw approach.

Republicans are the image of these efforts are "mediscare" tactical.

Ryan, speaking at a financial Summit in Washington said Obama and Democrats had decided of "shamelessly distort and demagogue Medicare,"and warned that without reform,"it went bankrupt and we will go in a debt crisis."

Former President Bill Clinton, who waited to be re-elected for a second term to address the reform social, warning the Democrats against the use of insurance for "political gains in the short term."

Now, freed from the political constraints of Office, Clinton flatly said fellow Democrats: "we have to deal with these things." You can't have healthcare devour the economy. ?

Optimistic rock on Avastin in cancer of the ovary

ZURICH - Roche Holding AG, the world leader in Oncology medicines, struck an optimistic tone about the Outlook of its key Avastin drug approval in ovarian cancer prior to a meeting important industry next month.

Head of pharma group that Pascal Soriot told journalists Thursday he was confident Avastin will win European approval and it was also relatively optimistic for win U.S. drug support.

"In Europe... we are confident because generally in Europe you can get approval on the basis of data of good progression-free survival," Soriot said.

"In the United States, we still wait until the data are fully mature to see what the overall survival data are similar and get a good sense of the FDA response, but I must say that we have seen so far... we made relatively optimistic that we have a good chance at the United States.". Thus, "he says.

Application for Avastin, used to treat a range of tumours, has fallen over recent quarters after the drug was struck by the movements of the two sides of the Atlantic health authorities to limit its use in breast cancer.

Roche now rely on the use of the vendor of billions of dollars to treat cancer of the ovary to stimulate growth future sales and intends to submit for the approval of the United States, later this year once he gave overall survival. She has already filed for approval in Europe.

"We will demonstrate that avastin has an essential role to play in cancer of the ovary," Soriot said before the Conference of the American Society of Clinical Oncology (ASCO) earlier this month next to Chicago.

"Overall superb new data showing our pipeline progresses." We hope that the shift in the perception of Avastin, "Soriot said, referring also data on lung and skin cancer drugs that will be presented at the ASCO."

OPPORTUNITY BUSINESS

Roche will present data impact on MetMAb of lung cancer and was to produce this treatment for approval in 2014, Soriot said, adding that Roche also sought to develop the drug in other diseases such as breast cancer.

Doctors and investors will be also eyes studies on vemurafenib, a drug to treat the deadliest form of skin cancer.

Soriot, said the business opportunity of vemurafenib has been limited to the skin cancer metastatic because the smaller number of patients in this parameter, but there is more potential sales if it were to be developed in the adjuvant.

The Group has yet to decide on setting prices of treatment and has therefore not yet a peak estimate sales for it.

Drug of rock, which develops with private holding Plexxikon and ipilimumab, an experimental drug developed by the US group Bristol - Myers Squibb, are giving hope to patients who already had a few treatment options.

Soriot said there was a place for both agents and it looks vemurafenib as the first line of treatment in patients who are positive BRAF.

"Ipilimumab is a different officer." It is a compound based on the immune system to treat cancer. It is a drug which can potentially be given to all patients, while vemurafenib can only be given to patients who are positive BRAF, which is approximately 50% of patients with cancer melanoma, "Soriot said."

"It is important to keep in mind that the percentage of patients who respond really well to ipilimumab is relatively limited." These patients have a strong response, but it is a small percentage, probably 10 per cent of the patients, who meet, "he says.

Spanish poet honors overlooked hero of the Warsaw Ghetto

MADRID - largest second poetry prize of the Spain was awarded this year to a volume honoring the heroines overlooked, including Irena Sendler, who saved 2,500 Jewish children by their smuggling of the Warsaw Ghetto.

Sendler has been nominated for the Nobel Prize for peace in 2007, a year before his death. She lost to former US Vice-President Al Gore and the Intergovernmental Panel on climate change.

"It is quite clear that it could have been truly worthy recipient of the award (Nobel Prize), no question, said Fatima Frutos, winner of the poetry Kutxa Ciudad de Irun 2011 Prize, ahead of an international field of 204"

"The visibility of women must be justified, those that have been considered secondary, who had no recognition but deserve that and much more."

Frutos also recalls Artemisia Gentileschi, a prominent painter of 17th century Italian and Spanish of the 19th century writer Carolina Coronado, which is struggling to achieve recognition in the fields then dominated by men.

Moreover, it honours, among others, Carl von Weizsaecker, a nuclear physicist of the 20th century, who would later become a philosopher.

"I start with the stories and build their lyricism and poetry, to assert their verse by verse," she said. "It is not only about giving visibility to invisible women, but also to the geniuses of the 20th century whose work has yet to shake up the consciences of the 21st century."

The volume of the recipient of the "Andromeda Encadenada" (encha?né Andromeda) takes its title from the Greek mythological Princess who was chained to a rock, but figure that Frutos sees as a source of inspiration rather than a victim.

It follows his 2009 volume "De Carne y hambre" (of flesh and hunger), which won the international prize of the erotic poetry of Ateneo Guipuzcoano.

"The myth allows me to discover other women as she who, in real life, through extreme, but nevertheless came through, if not euphoric, then at least optimistic and stronger,"Frutos say.""

"Andromeda" also adopts a perspective of pan-European topical with poems dedicated to the 18th century German philosopher Novalis or lyric poet of the 19th century studied.

"Now there are many reasons to defend European culture, the European ideal, the feeling that there is no European first or second class, but that we all in this together," she said.

Frutos main inspiration as a writer was Miguel Hernandez, a Spanish poet who died in prison in 1942, during the dictatorship of Francisco Franco.

"Hernandez were inoculated we poison blessed poetry so that we can grow without rancor but with force to advance social justice," said Frutos, who works as an agent of the equality of the local government.

The price of Irun is the second valuable most award for poetry in Spain and is open to all writers in Spanish. When she collects the award on May 28, Frutos devote to his grandmother, who took her reciting poems by Hernandez, she had learned by heart, because she cannot read or write.

"She wakes without rancor with poetry." She knew how hard-hearted me with as to hands and cover me with stanzas by great writers, "she said."

"I am a poet because of it." It must be said that an illiterate woman who lived in poverty also knew how to raise an international poet laureate. ?

Charity pulls smart stunt on pregnancy Bruni rumours (Reuters)

DEAUVILLE, France (Reuters) - at a glance of smart advertising, charity leader traded on rumours of possible pregnancy of Carla Bruni-Sarkozy to try to save the lives of babies in developing countries.

Before the Summit of the G8 rich countries who made the cut infant mortality a major theme in recent years, World Vision activists delivered a basket to the first lady of France with a kit of easily available in France delivery.

"What are simple products that any woman in Europe or North America can obtain at the pharmacy, but are inaccessible for many women in the developing world", Geraldine Ryerson-Cruz of the charity World Vision of Britain told Reuters.

Ryerson-Cruz said his charity is fighting to try to ensure that children around the world have the same chance of survival than the "first baby" French would have.

The French presidential palace has confirmed the pregnancy of Bruni, but the father of the President of the last week, Nicolas Sarkozy told a German newspaper that Bruni expects a child.

In the historic Villa Strassburger, World Vision activists delivered a basket with vitamins for pregnant women, a kit of safe delivery and hygiene supplies.

The basket was alcohol, surgical gloves, a razor blade for cutting the umbilical cord and sterilization baby care products.

Friday, Bruni will host first ladies of African nations participating in the Summit.

"As a French woman, Carla Bruni-Sarkozy is 150 times more likely to survive pregnancy and childbirth than a woman in the former French colony, Chad," Ryerson-Cruz said in an interview.

Ryerson-Cruz said that baby of the Bruni is also 52 times more likely to survive until the age of five as a baby with Chad, which has one of the worst years of child mortality in the world.

Sarkozy welcomed the leaders of the eight richest countries of the world to the posh seaside seaside Deauville Thursday and Friday. Several North Africa and sub-Saharan African heads of State will also attend the meeting.

Ryerson-Cruz said that estimates of Global Vision that mainly thanks to the initiatives of the g-8 in recent years the number of preventable deaths by the vaccination of children around the world declined approximately $ 4 million to approximately 8.1 million in 2010, 12.4 million in 1990.

DERMA Sciences foot-wound drug shows promise (Reuters)

BANGALORE (Reuters) - Derma Sciences Inc. said foot ulcers in 85% of diabetic patients healed completely after treatment with its experimental drug at the end of a trial of 24 weeks, improve its chances of licensing of the drug with potential partners.

Shares of the company, which specializes in wound care products, jumped 25 percent to a peak more of three months from $11.65 in afternoon trade on Wednesday on the Nasdaq.

Data will help the company to the outlicensing of the rights of the ex-états-Unis of the drug, code-named DSC127, a potential partner, Chief Executive Edward Quilty said in an interview.

Rodman & Renshaw analyst Michael Higgins said: "I think, the data from 24 weeks increased the bargaining power of the Derma with potential collaborators.

Higgins, who has a "market" to outperform rating on the stock, said that more impressed with the drug's ability to heal injuries 13.5 week earlier than the placebo.

The DERMA Quilty, said: "we certainly do not have the kind of money necessary to complete this test (late stage).". We (says the) Investment Committee that we were looking at all options available to us to help finance the trial. ?

Other that DSC127, Derma outlicensing may raise up to 50 million dollars of market fairness in its existing shelf registration statement.

Quilty, said most of the potential partners wanted to watch 24 weeks data and comprehensive benefits data, which will be submitted to the U.S. Food and Drug Administration.

It is expected to associate the drug later this year or early next year.

Barry Wolfenson, Executive Vice President of global marketing & business development, said: "I think that the real activity on partnerships for this will begin this week that we announce the data and begin to assemble a package and reach potential partners around the world."

If approved, the Derma drug is in competition with Johnson & Johnson Regranex for treating deep ulcers neuropathic diabetic foot.

"We believe that our data is stronger than Regranex," said Wolfenson.

If approved, DSC127 was rake up to 500 million dollars in annual sales to the United States, he said.

DATA FROM 24 WEEKS

The company said 85 percent of patients having completed protocols for eligibility, or population by Protocol (PP), has shown complete cure at 24 weeks, compared to 52% in the placebo group.

In the intent to treat population, where all patients are included, 73 per cent showed complete cure at 24 weeks, compared to 46% in the placebo group.

DERMA Sciences was developed to test the drug in two of the forces of dose and placebo controlled arm.

The trial showed a statistically significant difference in healing of the PP population at 24 weeks.

DERMA Sciences plans to begin trials of late phase of the drug in the first half of 2012. (Reported by Anand Basu in Bangalore.) (Editing by Prem Udayabhanu, Maju Samuel)

Women with high insurance subject to stop cancer drugs

 women taking breast cancer drugs are more likely to skip days or abandon processing entirely if their coinsurance is high, American researchers have found.

There is nothing new that people will often take the medicine that prescribes their doctor, but for cancer drugs, the consequences could be disastrous, experts say.

"Here we are talking about a drug to save lives,", said Dr. Alfred Neugut of Columbia University Medical Center in New York, whose results appear in the Journal of Clinical Oncology.

"Drugs are that important, perhaps that we put in place mechanisms to provide the means to circumvent the insurance or franchises."

Some insurance companies already have programs in place to ensure lower insurance for certain drugs, Neugut said, but they do cover inhibitor of aromatase, the focus of the new study.

These drugs, including Arimidex (AstraZeneca), significantly reduce the risk of death in cancer survivors who have been through menopause.

Arimidex can now be purchased as a generic drug for only less than a dollar by the pill, drug cost more than $2,000 per year when the study has been completed.

Neugut and colleagues used data from claims of MedCo Health Solutions to find out what role co-insurance patients could play or not, they took drugs for the recommended five years.

More 8 000 women aged 50 to 65, 20 percent stopped the drug at the beginning if their coinsurance was less than $30.

However, if the payment was $90 or more, 23 percent dropped drugs in advance.

For older women, the gap was five almost percentage, which Neugut chalks less available income.

There are similar differences in the number of women who jumped at least 20 per cent of the days, and the gap remained the same after researchers have considered possible explanations such as income and other factors.

"If the co-insurance gets too high, it will prevent people from taking a drug they really need," said Neugut, adding that previous research has noted the same effect for orders as a whole.

With health reform, more people should be covered by Medicaid, which means that they will have lower co-insurance. Neugut said that it is unclear what effect which were, in view of the beneficiaries of Medicaid but have fewer resources first.

He said that the problem is more serious for medicines against cancer than for other drugs, because the former deals with a potential fatal disease.

In addition, cancer drugs have side effects, which may also discourage women from taking them.

In General, Neugut told Reuters Health, "less than 50 per cent of women actually complete the five years - and if you do not, you lose most or all of the benefit of therapy."

Ejaculation ampio drug shows promise

BANGALORE  - Ampio Pharmaceuticals Inc. announced its drug to treat ejaculation showed statistically significant results in a late trial in Europe.

The drug, called Zertane, is regarded as needed before sexual activity and is not necessary to be taken on a daily basis.

Ampio said "the analysis of the results of the trial has exceeded our expectations." The company expects that the results of this test will allow the file to European regulatory approval for the drug. In his statement today, the company did not plans to market Zertane to the United States.

The active ingredient in Zertane is hydrocloride tramadol, which has been used to relieve the pain since the mid-1990s. Ampio specializes in "repositioning" drugs, i.e. testing of already approved drugs to find treatments for new indications.

Ampio said in a statement that ejaculation is the most common male sexual dysfunction, including about 23% of all men aged 18 to 75 years.

Death of Joplin tornado up to 122, eighth more deadly on record (Reuters)

JOPLIN, Mo (Reuters) - a tornado of monster which ripped through the small town of Missouri southwest of Joplin Sunday killed at least 122 people and wounded about 750. authorities, said Tuesday

The number of dead revised 118 deaths made earlier Tuesday and makes it the giant tornado the eighth deadliest in the history of the United States, according to officials speaking at a press conference of.

The authorities also said that Joplin tornado has been upgraded to an EF-5, or the best possible rating on the enhanced Fujita of the power of the Tornado and the intensity scale. Joplin tornado had previously been assessed as an EF-4.

EF-5 tornado are rare in the United States, but already this year there were at least four - two in Mississippi, Alabama last month and Joplin. They are so destructive that experts have said that they can transform a House into an air missile. During the Joplin tornado winds were estimated at up to 200 miles per hour.

The tornado damaged Joplin a approximately 8 000 structures in the town of about 50,000, said authorities.

(Megan Gates reports;) Written by Greg McCune. (Editing by Jerry Norton)

Most cancer patients, such as full access to files

NEW YORK - Cancer patients who were given full access to their medical records at the beginning of the said treatment records helped to understand and discuss their disease with others, and they were not more concerned than other patients in a new study of the France.

There was a tendency to improve patient access to their own health information, some physicians fear that give full records patients will increase their anxiety, the authors note in the journal Cancer.

But Dave deBronkart, a prominent blogger on the participation of the patient since his own recovery from advanced kidney cancer, argues that full access is useful.

deBronkart, who blogs as "e-patient Dave", told Reuters Health via e-mail, "detailed information on the disease are important for the patient to make informed decisions." It also allows the patient and his family to cope better. ?

Participants in the new study included approximately 300 patients who had been recently diagnosed with cancer of the breast, cancer of the colon and lymphoma and started chemotherapy treatment.

Dr. Gwenaelle Gravis of the Paoli-Calmettes Institute in Marseille and colleagues randomly these patients in both groups.

In a group, patients received information in the usual manner for their institution - doctors could give patients their medical records if they chose, and patients may ask to see records on their own. In the other group, all patients who have accepted received their full medical records in a Briefcase with a user guide and were said to carry the Briefcase appointments so that records could be continuously updated.

In the beginning, middle and the end of the treatment, the researchers asked patients about their level of anxiety. Also, they gave participants a survey on quality of life and has asked on their understanding of their disease and treatment experience.

Anxiety levels were not different between the groups at any time during the treatment, and patients in both groups have also reported a quality of life like at the beginning and the end of chemotherapy.

Well that more than patients who received their full medical records saying that they were completely satisfied with the information they received and feel fully informed, this trend was not passed statistical tests to show a difference between groups.

The majority of patients who have received their complete medical record, said that the records helped to understand their disease in more detail and discuss with family members and physicians.

About 70 per cent of them said that if they had the choice to go back, they would receive their full file again.

Some patients complained that Briefcase with their records was too heavy to carry, or that its color was"inadequate", and a few others, has stated that they had insufficient information, or that it is difficult to organize the information that was there.

Gravis and his colleagues noted that giving patients a full access to their medical records could help foster confidence in their doctors in the long term, and it was easy to do.

deBronkart says he is "sick of people being in the institution, regardless of what say patients we want, think it is in our own interest if they make that decision for us."

"There is evidence that the majority of patients with cancer would like to receive as much information as possible", he added.

The authors cautioned that most of the patients had stage cancer with a good prognosis, and the results may not apply to patients of different types of cancer.

Peter Schmidt, Chief Information Officer at the National Foundation of Parkinson, who was not involved in the study, said it may also be useful for patients to have access to an "Adviser to medical records", because some files may have confusion of information.

Researchers have said that a study is needed on the responses of patients to access medical documented in other situations and circumstances - including in the context of electronic medical records, which could allow easy patientsconfidential access to the House.

They concluded that in this study at least, "allowing full access to the folders medical personal satisfaction increased without increasing anxiety in patients with newly diagnosed cancer.".

Irregular periods in adolescence linked to health risks

NEW YORK - teenagers who have irregular periods are more likely to be overweight and to have signs of early warning of diabetes and diseases of the heart than those with menstrual cycles regular, a study said.

While the link between the irregular periods and cardiovascular diseases and diabetes is well established older women, the results, published in "fertility and sterility" suggest that doctors may be able to identify this risk much earlier - and try to do something.

"There may be a false idea of adolescent medicine...".that ' takes a few years after the onset of the first rules to get the engine running "and therefore could not want to worry about irregular menstrual cycles among adolescents until much later," said Charles Glueckl' one of the authors of the studyof cholesterol and Metabolism Center at the Jewish Hospital of Cincinnati.

"This is clearly wrong", he added, noting that even in young teenagers, very irregular menstrual cycles are not normal and should not be ignored.

Glueck and his colleagues followed 370 girls, 14 years, the study more initiated by the National Heart, Lung and Blood Institute.

Once each year, girls were requested how long he had been since their last menstrual cycle. Researchers periodically measured their levels of various hormones, glucose and insulin and blood pressure.

They also collected information on girls height, weight, and waist circumference.

The authors have defined irregular menstrual cycles as a term more 42 days, a test which meant to catch the 2 per cent of girls with less regular periods, said Glueck.

Aged between 14 and 19, 269 of girls reported regular periods to each annual visit. A further 74 of them were that a single report of an irregular period, 19 girls had two reports and eight said he was at least 42 days since their last period at three or more visits.

Girls with most of the reports of irregular periods were already heavier than others at the age of 14 years and has acquired more inch on size and weight during the study. They also had higher testosterone levels.

By age 25, those who had not reported a period a mean body mass index (BMI), a measure of weight against height of 26.8. Those who had reported irregular periods to three or more appointments had an average of 37.8 IMC while the girls who reported one or two irregular periods have BMI somewhere in the middle.

Reports of irregular periods have also been linked to higher levels of sugar in blood and insulin for 25 years.

Authors could not be sure what is happening with cycles menstrual girls' during the rest of the year. Also, the findings do not prove that irregular periods cause girls to take weight or are responsible for the increase in the levels of glucose and insulin - rather, the irregularity could be another problem.

It is possible that the ovaries may respond to changes in metabolism, such as increased insulin levels, said Alice Chang, endocrinologist UT Southwestern Medical Center, suggesting that some of the risks associated with diabetes came before problems with ovulation.

Irregular periods may be a sign of Polycystic ovary syndrome, or PCOS, which can cause fertility problems, said Glueck. But in adolescence means it can be "very successfully treated."

Chang, who was not involved in the latest study, agreed that the implications for the central offices are an important study message.

"When I see women diagnosed with PCOS, often have symptoms during adolescence, but it is not being set for them." "We must be more aggressive in adolescents on the treatment of central offices and treatment of obesity," she said.

Gluten not linked to the risk of babies of diabetes: study (Reuters)

NEW YORK - for babies at higher risk of diabetes in children because of family history or genes, a gluten-free diet in the first year of life not the chances of developing the disease lessGerman researchers report.

The conclusions are undermining previous studies, including the work of the same scientists, which suggests that babies exposed to gluten in their early diet may be more likely to develop type 1 diabetes later in childhood.

Although the new study included only 150 children, Dorothy Becker, Director of the program of diabetes in children's Hospital of Pittsburgh, told Reuters Health that the results are clear enough.

"This does not mean that it if you have made a huge study, it would be an effect (gluten)," said Becker, who was not involved in the study. "But it makes it unlikely."

Gluten is the protein in wheat and other cereals which makes the elastic dough and gives the bread its chewiness. About 1% of the population of the United States have a condition called celiac disease, in which the immune reactions to gluten damage the intestines.

Every year kids about 20 per 100,000 aged of less than 10 to the United States receive a diagnosis of diabetes type 1, according to the National Institutes of Health. In contrast to type 2 diabetes, which is usually a disease of adults and associated with old age or of obesity, diabetes type 1 generally child impactors.

Many of them probably inherited a genetic predisposition to the disease of their parents. Yet only genes not fully explain why people develop the condition. It is believed that other factors such as environmental exposures, are necessary for the trigger.

In the latest study, researchers followed 150 babies at least one parent or a brother had been suffering from type 1 diabetes - marked by the death of the cells of the pancreatic islets secrete insulin hormone. The body requires insulin to convert food sugars into energy.

Half of children have been exposed to gluten in their diet for the first time at the age of six months. For the rest, the exposure to the protein has been delayed until after their first birthday.

It seems that different regimes have no impact on the ability of infants to grow or to take the weight.

At the age of 3 years, three children exposed to gluten initially had developed diabetes type 1, compared to four in the exposed group signs that children had developed for immune reactions to their own cells of pancreatic islet - a possible precursor to diabetes.in particular in those with a genetic predisposition for the disorder - appeared in gluten of 11 children, given six months of age, compared to 13 who ate first of gluten when they were between the ages of 12 months.

Some research suggests that delaying exposure to gluten can increase the risk of developing celiac disease. However, the German scientists have said that they found no evidence of such a link.

Approximately 30 per cent of parents said they did not strictly follow the diet plan. Still, researchers said, the results of the study show that while delaying the introduction of gluten in the diet of the baby causes no harm, it seems reduce the risk of diabetes or immune-early indicators of insulin problems.

Researchers have not responded to requests for comments on their study, which appeared online month last in the journal Diabetes Care.

Research on other triggers of potential foods for type 1 diabetes is underway. Last November, researchers Finland reported that infants with a genetic predisposition to type 1 diabetes who were fed infant formula called Nutramigen were probably half as those forms of cow's milk conventional to show signs of Autoimmunity of islet cells later in childhood. Milk protein in Nutramigen (sold as Enfamil by Mead Johnson & Co.) are altered in a way which makes them more tolerable for the immune system.

Becker helps lead a large international trial funded by the National Institutes of Health to explore the findings of finishing. The results of this study, which includes about 2 200 babies, are expected in 2017, she said.

McDonald shareholders reject the proposal of obesity

OAK BROOK, Illinois  - Corp. McDonalds spurned calls to assess the impact of food on obesity and said that its trademark clown Ronald McDonald would be peddling Happy Meals for children for the years to come.

"It's choice and we believe in the democratic process," Chief Executive Jim Skinner told a packed auditorium meeting of its shareholders, to an enthusiastic wave of applause. "It is on the personal and individual right to choose."

The largest chain of fast food of the resounding world shareholders rejected a proposal that would have required to publish a report describing its role in the epidemic of childhood obesity, saying customers were free to make their own food choices.

Ronald McDonald is an Ambassador McDonald and is an Ambassador for good. Ronald McDonald is going nowhere, "Skinner said firmly, which prompted most cheers with shareholders."

Among the dissidents at the meeting was Dr. Donald Zeigler, Director of prevention and the health of living to the American Medical Association, who asked when the burger chain will stop marketing to children with Ronald McDonald.

Zeigler, who is also visiting professor at the University of Rush Medical Center, was one of the 550 health care professionals who signed an open letter to the McDonalds plead that he "stop take sick next generation."

Tuesday, a monitoring group placed ads in newspapers across the country claim McDonald is to stop marketing to children across the clown, gift toy and other tactics.

Some 17 per cent of children and adolescents are obese, according to the Centers for Disease Control and Prevention. Excess weight in childhood raises the risk of developing type 2 diabetes, high cholesterol, hypertension and a host of other diseases.

McDonald has been a lightning rod for criticism over the years on its marketing tactics and sales of Happy Meals for children that include toys as incentives.

McDonalds allows parents to share of milk or juice of soda in its Happy Meals. It also offers slices of apples with sauce caramel and chicken nuggets and alternatives to the French fries and burgers.

The restaurant chain said healthier options on its menu, including salads and oatmeal, but critics argue, that it is still too fat, salt and sugar in his meal. Even the oatmeal, one critic noted, contains about as much sugar as a Snickers candy bar.

Skinner has defended the strategy of McDonald, which resulted in hefty sales and earnings for shareholders. Shares of McDonald won almost 12% in the last four months and agrees with a record of $82.63 Thursday.

But, as noted by the experts, obese children often grow obese adults, overloading the system of health care.

Ironically, Miles White, Chairman and CEO of diversified health Abbott Laboratories company, is a Director of the Board of Directors since 2009 McDonald.

Abbott made a wide range of drugs, including cholesterol-lowering statins, and medical devices, such as heart stents used on patients with clogged arteries.

Growth in sales of generic drugs SUV overall slashing

NEW YORK - global growth in sales of prescription drugs could be cut in half over the next five years as lucrative brands lose patent protection and cheaper generics and emerging markets become important growth engines, according to IMS Health

"Past expenditure trends offer some clues on the level of growth until 2015," said Murray Aitken, a leader of IMS Health including division conducted the study.

"There are dynamics involved, which are driving unprecedented rapid changes in the composition of expenditures by patients and payers between branded and generic products," said Aitken, whose society followed trends and the sale of prescription drugs.

Average annual sales should grow by 3 to 6 per cent during the period, reaching almost here $ 1.1 billion in 2015. But the trend reflects a slowdown in the annual growth of 6.2% observed over the past five years, said the report.

The United States sales rise only 0 to 3% per year over the period, while sales in Europe will increase from 1 to 4 per cent. Brand drug expenses should be changed little in these markets developed by 2015, with growth coming instead from the demand for less expensive generic drug manufacturers.

A wave of the new generic approach as an unprecedented number of big drug loses patent protection U.S. by 2015, including the control of Pfizer Inc., 10 billion dollars per year cholesterol fighter Lipitor, Bristol-Myers Squibb Co Plavix blood clot and Zyprexa Eli Lilly and the Commander of schizophrenia.

Aitken said too few new drugs are being approved to offset lost sales of those facing the onslaught of generics greatly.

"We continue to be disappointed by the number of new chemical and biological entities in the market," he said.

Altogether, less expensive generic formulations of drugs due will produce from $ 98 billion in net savings to insurers in the developed until 2015.

"The part of the United States of expenditures spent 41 per cent in 2005 to 31% in 2015, while the share of the budget devoted by the countries of Europe top 5 from 20 percent to 13 percent," said the report.

During this time, he said spending will probably double over the next five years in new markets, 285 million to 315 million per year, or approaching the United States levels.

"Seventeen emerging markets growth high, led by China, will contribute to 28% of the total spending by 2015, instead of only 12 per cent in 2005," said the report. He noted that growth will be come mainly from generics.

Overall spending on cancer drugs expected to reach 75 billion dollars here, 2015 amounting to a much slower pace than in the past five years, as many more recent treatments and expensive biotech are already widely used in developed markets.

But the annual expenditure on medicines diabetes should increase by 4% to 7% until 2015, due in large part to the changing of regimes and ways of life in developing countries to increase the prevalence of Type II diabetes.

Engaging drama of "Declaration of war" of cancer in children (Reuters)

CANNES (Hollywood Reporter) - "Declaration of war", the function of Gauls sophomore writer-director-actress Valerie Donzelli, which opened the Cannes critics week, is a commitment, but not quite convincing representation of a battle that began when his minor son of filmmaker was diagnosed with brain cancer.

Filled with Nouvelle Vague atmosphere, punctuated by musical montages and sudden gusts of feeling, "War" was right weapons to conquer arthouse audiences both at home and abroad, giving the young French author more international visibility.

Based on of Donzelli and writer-star and ex-boyfriend of the Jeremie Elkaim life real test, the story is autobiographical, through, in him giving a scale which would have been more difficult to nail down in a purely fictitious tale. Reality factor also allows the duo to engage in many flights of fancy, sprinkling their story of everything: a Magnolia-style sing-a-long a romance quickly edited directly "Jules and Jim."

Yet, by engaging in a range of styles, which were already amply exposed small budget of the 'The Queen of heart' Director debut - and in relying on a great soundtrack to film hits which includes everything from J.S. Bach to Laurie Anderson "Superman" the drama is broadcast by some attempts of too numerous to be cinematically spontaneous and perhaps even too revealing cute at certain intervals.

Despite these snags, there are still several times tearing in the tale of young lovebirds (Donzelli) Juliet and Romeo (Elkaim), including electrical during a party meeting is soon followed by the birth of their son, Adam (Cesar Desseix), an adorable toddler little begins to show signs of alarming disease. After a few more in most disturbing of doctor visits - and Donzelli is at its best by revealing aspects tragicomic France labyrinthine hospital system - a tumour is detected in the brain of Adam, initiating a long period of fear, confusion and anticipation that no parent would want on their worst enemy.

Jump (and sometimes jump-cut) chronologically to the period of four years in which Adam was submitted to major surgery followed by chemotherapy treatment, Donzelli focuses less on procedures medical raw on the way in which parents face, or cannot cope with the affliction. In this sense, war is not in contrast to the recent "rabbit hole", except that here there is still hope that the child will survive, although such hope is so exhausting to maintain that he eats away relationship Juliet and Romeo.

Ultimately, it is regrettable that Donzelli and Elkaim, appearing in a total of five films in various sections of the Cannes this year are no more on their chops acting to support the weight of what was clearly a traumatic experience for each of them. This is particularly frustrating in coils, the latter film, as important aspects of the plot are hidden via voiceover or constant use of music.

Technical achievements are the worlds above Donzelli freshman effort, with colourful imagery crisp by Sebastien Buchmann ("Memory Lane") which makes it a pleasure to battle to look at.

Scientists are "master switch" genes for obesity

London - scientists have found that a gene linked to diabetes and cholesterol is a "master switch" which should help controls other genes found in fat in the body and say in the search for treatments for obesity-related diseases.

In a study published in the journal Nature Genetics, the British researchers said that, because fat plays an important role in the susceptibility of people to metabolic diseases such as obesity, cardiovascular disease and diabetes, the regulator gene may be target for drugs to treat these diseases.

"This is the first major study that shows how small changes in a single master regulator gene can cause a cascade of other metabolic effects in other genes," said Tim Spector of College London of the King, who led the study.

More than half a billion people, or of 1 in 10 adults worldwide are obese and the numbers have doubled since the 1980s as the obesity epidemic overflowed rich in poor countries.

In the United States, obesity-related diseases already represent about 10% of medical expenses--147 billion more per year.

Type 2 diabetes, which is often linked to poor diet and lack of exercise, is reaching epidemic levels in the world as the rate of increase of obesity.

Scientists have already identified a gene called KLF14 as being related to 2 levels of cholesterol and diabetes type, but until now, they knew what role he played.

Spector team analyzed more than 20,000 genes in fat samples under the British 800 volunteers female twin skin. They found a link between the KLF14 gene and the levels of many other genes in adipose tissue, showing that KLF14 acts as a master switch to control these genes.

Then, they confirmed their conclusions 600 fat samples of a distinct group of people in the Iceland.

In a report of their study, the researchers explained that other genes were to be controlled by KLF14 are linked to a range of metabolic traits, including body mass index, obesity, cholesterol, glucose and insulin levels.

"KLF14 appears to act as a general switch, control processes that connect changes in the behaviour of subcutaneous fat of disturbances in the muscles and the liver that contribute to diabetes and other conditions," said Mark McCarthy, of the University of Oxford of Britainwho also worked on the study.

"We are working hard... to understand these processes and how we use this information to improve the treatment of these conditions."

Selenium does not prevent cancer: report (Reuters)

NEW YORK (Reuters Health) - there is no convincing evidence that the fact to the high doses of selenium - a popular dietary supplement - can prevent cancer, according to a new review.

Selenium is a mineral that is essential for humans and is also present in the soil and rocks.

Although the recommendations of daily selenium of the United States and the World Health Organization vary between 30 and 55 micrograms per day for adults, the authors note, companies selling supplements claim that higher doses have a range of health benefitsincluding the prevention of cancer.

However, Mr. Marco Vinceti, one of the authors of the new journal of the University of Modena and Reggio Emilia, in Italy, "we have still not an accurate picture of what Selenium is for human health," said Reuters Health.

To try to get better attention on this image for cancer in particular, Vinceti and his colleagues reviewed 55 studies on the relationship between the different types of cancer and selenium.

Most of those that have so-called "observational studies" - scientists measured how much selenium people ate every day or how much they had in their blood or nails, then followed which has cancer over the next few years.

The other 6 studies have been conducted through more rigorous testing, in which researchers divided randomly participating in a group which took supplements of selenium for a month or more and the other took a pill without drug placebo or nothing - then follow their cancer. It is believed that these types of studies are better accounting of external factors that may affect cancer risk.

Observational studies suggested that speak of selenium can be linked to a slightly lower risk of cancer - both men and women.

But in randomized trials, people assigned to take selenium at doses at least four times higher that the daily recommendation were not less likely to get cancer - prostate cancer and cancer of the skin in particular - those taking not of selenium.

And some of these tests has raised the question of whether doses of selenium could be dangerous, such as increasing the risk of diabetes.

The journal is published in the Cochrane Library, a publication of the Cochrane Collaboration, an international organization that evaluates medical research.

"If you place all together, it is not a good story for patients," Dr. Neil Fleshner, researcher at the Toronto University health network who has studied the effect of selenium on the risk of prostate cancer, told Reuters Health.

He said that it is always possible that selenium may help prevent cancer over a very long time period, or some types of selenium could operate while others do not. But good, "exists now that no good not evidence at all that Selenium is beneficial," said Fleshner, who was not involved in the control.

James Marshall, of Roswell Park Cancer Institute in Buffalo, said that the enthusiasm of selenium began with the evidence that animals or people very low selenium in the diet are at an increased risk of cancer.

While people could benefit from a supplement of selenium, is where the anti-cancer effects of the mineral appear at the end.

"Once you get an animal or a person to a place where the intake of Selenium is adequate, then, this is where the evidence has proved disappointing,"Marshall, who was not related to the research, said Reuters Health."

"Put on more selenium will not make them any good, and it may in fact their wrong," said Marshall.

Vinceti said that although few people in Europe selenium as a supplement, it is common to the United States.

Selenium supplements are about $2 a month supply.

Vinceti added that additional research is needed to determine the range of daily selenium which is beneficial for human health - as both too and too few seem to have health risks. In this regard, we are not at the end of history", he said.

But when it comes to cancer prevention, at least for the moment, the evidence is not there.

"There are several ways of preventing cancer, but put more selenium...".on your breakfast cereals, is probably not one of them, "Marshall concluded."

SOURCE: http://bit.ly/iqHcFo The Cochrane Library, online on May 10, 2011.

Risk factors increase in Korea "Westernize" heart

NEW YORK - as Korea to become more "Westernized" since the 1990s, the number of adults with multiple risk factors for heart disease and diabetes has risen gradually, a new study finds.

The findings, the researchers that call for prevention efforts better to slow down the trend - and, more generally, the importance of a healthy diet and exercise for all in developed countries.

The study, published online by the journal Diabetes Care, looked rates changing the Korea of the metabolic syndrome, a collection of 2 type diabetes risk factors of heart disease and stroke.

People with metabolic syndrome are generally at least three of several risk factors, including abdominal obesity, high blood pressure, elevated blood glucose levels, low level of "good" HDL cholesterol and triglycerides high (a type of blood fat).

In 1998, the study concluded, 25 per cent of adults 20 years old and up Koreans had metabolic syndrome. In 2007, that figure had risen to just over 31 per cent - close to the speed of 34% seen in the United States at the time.

The increase came in a period of rapid in Korea economic growth and less healthy lifestyle changes that often come with him, according to the researchers, led by Dr. Kwang Kon Koh Gil Medical Center in Incheon.

Koreans eat more food "Westerners", TV more and get less exercise than ten years, the team of Koh says in the report.

And this, they write, the importance of the lifestyle of the risk of metabolic syndrome for everyone.

The findings are based on a study of the periodic Government of Korean adult health 20 years and more. Between 1998 and 2007, the team found Koh, the prevalence of the metabolic syndrome has steadily increased - with abdominal obesity, low HDL and triglycerides high all growing more common.

One positive was that the rate of hypertension tempered. That the researchers write, perhaps because the Korean traditional diet is rich in salt, and with changes in diet of Koreans in recent years, salt consumption has decreased.

The study is not the first to find emerging Western-style health problems in Asian countries, through rapid economic growth.

A recent study in urban India regularly found rates of obesity, hypertension and diabetes in young adults, researchers up followed by seven years.

These researchers put a large part of the responsibility on the lower levels of physical activity and high rates of smoking.

Cardiovascular disease and diabetes as increasing problems highlighted several other recent studies in the South and Southeast Asia. A study of the World Bank, the India and other South Asian Nations, said that the people of the region suffer their first heart attack at age 53, on average, six years earlier than people anywhere elsewhere.

To help combat Korea stage problems, Koh team writes, "changes in mode of life, such as regular physical activity and a healthy diet with low sodium, carbohydrates and lipids, should emphasize.

Public Citizen: data key left of Alzheimer's disease study (Reuters)

CHICAGO (Reuters) - a group of U.S. consumers alleged Tuesday that researchers with ties to Eli Lilly and Co withheld important information of a medical journal in their study of a drug of Imaging for Alzheimer's disease.

In a letter published in the Journal of the American Medical Association, Public Citizen criticized a study on 19 January that assessed the effectiveness of the scans of the brain to help Lilly Amyvid, dye experimental to detect abnormalities of the brain.

They said that the authors of the study excluded data on how accurately the scans have been interpreted by a doctor to another.

"Conceal important information, were induced the newspaper and its readers to believe that this test to identify abnormalities of the brain was more reliable than it actually is," Dr. Michael Carome, Director Assistant of the Public Citizen health research groupwritten.

"Given what you know of Alzheimer's disease and the lack of effective treatments, no test for the diagnosis of this disease must be proved to be very precise in studies of large, carefully before it is approved by the FDA for marketing"carome."said."

Lilly strongly dispute their claims, calling it "inaccurate."

"We have worked with the FDA to identify and specify all end points for the study of Phase III of Amyvid", the company said in a news release.

Lilly said all points of termination in the study have been met, and they have "communicated adequately."

In March, the U.S. Food and Drug Administration refused to approve Amyvid, citing the need to ensure the scans can be read accurately.

An Advisory Committee of the FDA said in January that it would take more data before approval.

Amyvid is designed to detect the plate of beta-amyloid associated with Alzheimer's disease in the brains of people living on a procedure for imaging called a computed tomography scan pet (pet).

A non-reliable test could lead some people to believe that they had Alzheimer's disease when they are not, and it could be others the false assurance that the did not have the disease, when they could, Public Citizen, said in an e-mail.

Lilly is to research the agent for use with pet market, to help doctors rule on the plate related to Alzheimer's disease, but do not to diagnose disease.

General Electric, and Bayer AG also develop rival products.

Lilly and his unit of Avid Radiopharmaceuticals have said they are trying to answer the questions raised by the FDA Advisory Committee and will continue to do so in an ongoing dialogue.

Currently, some 26 million people globally have Alzheimer's disease, the most common dementia form.

(Reported by Julie Steenhuysen.) (Editing by Laura MacInnis and Paul Simao)

Chronic use of acetaminophen related blood cancers: study

NEW YORK  - chronic users of acetaminophen painkiller risk slightly increased for cancers of the blood, according to a US study.

But the risk remains low and it is still uncertain, what role plays the drugs, the study, published in the Journal of Clinical Oncology, added.

Previous work has shown that the consumption of aspirin could reduce the likelihood of dying from colon cancer but increase the risk of bleeding ulcers, although the image has been less clearly blood or blood, cancer.

"A person who is age 50 or plu has a risk of 1% in ten years to get one of these cancers," said Emily White at Fred Hutchinson Cancer Research Center in Seattle, who worked on the study.

"Our study suggests that if you use acetaminophen at least four times a week for at least four years, which would increase the risk of about 2 %".

Noting that the present study was the first great foresight on the issue, as opposed to individual case reports, it added that there is still no evidence that acetaminophen can cause cancer.

New tests must also be confirmed before it is used in any decision regarding treatment.

White and his team followed 65 000 older men and women in the State of Washington, all free to the history of cancer, with the exception of cancers of the skin, at the beginning. First, they asked the participants on their use of pain relievers in the past decade.

Over six years on average, 577 people, or less than 1%, has developed a hematologic cancer.

More than 9% of those who, however, used large amounts of acetaminophen, compared to only 5 per cent of those who did not get sick.

After accounting for things like age, arthritis and family history of certain cancers of the blood, chronic users acetaminophen had almost twice the risk of developing disease.

No other pain relievers, including aspirin and ibuprofen, were tired at the risk of cancers of the blood.

White says that it is still too early to make recommendations based on the study, adding that they do pain relievers are free of side effects.

"Use long term of prescription drugs could have negative effects." "You have to weigh the benefits against the risk of all drugs", she added.